RxDoctor Payments DataLook up a doctor →

David Ramos, APRN

Family · Riverside, RINPI 1114227436

Payments from drug & device makers

$13,706in general payments, 2019–2025

Across 678 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Pfizer$928
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$13,706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,706 in reported general payments places this provider in the 95th percentile of 457 family providers in Rhode Island.

See all family providers in Rhode Island

Medicare billing

Part B allowed, 2024
$19,548
Medicare patients
78
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$94,659
TrulicityDulaglutide53$60,523
EliquisApixaban39$40,147
OzempicSemaglutide20$22,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,746
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$20,584
XareltoRivaroxaban20$19,703
Breo ElliptaFluticasone/Vilanterol20$13,349
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,545
JanuviaSitagliptin Phosphate15$7,099
Atorvastatin Calcium556$5,941
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,821
Omeprazole203$3,651
Rosuvastatin Calcium210$3,340
Albuterol Sulfate HfaAlbuterol Sulfate134$3,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$897$94,65975 claims
Lilly USA, LLCTrulicity$1,260$60,52353 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,070$55,67959 claims
PfizerEliquis$928$40,14739 claims
Novo NordiskOzempic$1,988$22,42720 claims
Johnson & JohnsonXarelto$439$19,70320 claims
MerckJanuvia$144$7,09915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 family providers in Rhode Island.

Other family in Riverside

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →